Adlai Nortye Ltd.(ANL)Earnings, Financials & Key Ratios
ANL•NASDAQ
$10.00
Price updated Jun 27, 2026
AboutAdlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trials to induce and stabilize PD-L1 dimerization and disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.Show more
- Revenue$0-100.0%
- EBITDA-$53M+18.8%
- Net Income-$52M+50.5%
- EPS (Diluted)-4.89+68.3%
- ROE-98.95%+25.1%
ANL Price & Volume
Adlai Nortye Ltd. (ANL) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Intensity Drives High Cash Burn
Investment Thesis • Updated 2024Q2
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial binary outcome
"Adlai Nortye remains a high-risk, pre-revenue biotechnology firm entirely dependent on the successful clinical progression of its lead oncology asset, AN2025. While the company has improved its equity position to $53.4 million as of 2024Q2, the ongoing $13.0 million quarterly R&D expenditure creates a precarious financial profile. Investors should monitor the binary outcomes of the Phase III BURAN trial, as the current $98.0 million cash balance provides limited runway against persistent operating losses."
Verdict Logic
the company's reliance on a single lead asset and its $14.2 million quarterly free cash flow burn rate present significant risks of total value destruction if clinical milestones are not met.
ANL Growth Metrics
Adlai Nortye Ltd. (ANL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM55.92%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM51.04%
Return on Capital
10 Years-71.95%
5 Years-71.95%
3 Years-94.18%
Last Year-103.79%
ANL Recent Earnings
Adlai Nortye Ltd. (ANL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (38%)●Beat Revenue 1/12 qtrs (50%)
Q2 2026Latest
Apr 10, 2026Metric
Actual
Est
EPS
$0.18-71.4%
$0.10
Rev
$5M+1077.0%
$450,311
Q4 2025
Dec 29, 2025Metric
Actual
Est
EPS
$0.18+0.0%
$0.18
Rev
—
$313,233
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.18+0.0%
$0.18
Rev
—
—
Q2 2025
Apr 30, 2025Metric
Actual
Est
EPS
$0.22+58.5%
$0.53
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 10, 2026 | $0.18vs $0.10-71.4% | $5Mvs $450,311+1077.0% |
| Q4 2025 | Dec 29, 2025 | $0.18vs $0.18+0.0% | —vs $313,233 |
| Q3 2025 | Aug 7, 2025 | $0.18vs $0.18+0.0% | — |
| Q2 2025 | Apr 30, 2025 | $0.22vs $0.53+58.5% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Adlai Nortye Ltd. (ANL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $10.00 | $312.37M | -2.05 | -100% | — | -98.95% | — | |
| $18.00 | $1.99B | -11.25 | 15.33% | -39.29% | -24.32% | — | |
| $24.15 | $1.78B | -22.36 | 38.87% | -126.33% | -0.25% | — | |
| $0.30 | $193.01M | -0.68 | 96.69% | -39.68% | -60.72% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $31.00 | $3.12B | -9.42 | -4.26% | -156.36% | -68.97% | — |
Compare ANL vs Peers
Adlai Nortye Ltd. (ANL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when ANL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ANL Frequently Asked Questions
Adlai Nortye Ltd. (ANL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Adlai Nortye Ltd.'s revenue?
Adlai Nortye Ltd. (ANL) reported $6.5M in revenue for fiscal year 2024.
How fast is Adlai Nortye Ltd. growing?
Adlai Nortye Ltd. (ANL) saw revenue decline by 100.0% over the past year.
Is ANL profitable?
Adlai Nortye Ltd. (ANL) reported a net loss of $54.1M for fiscal year 2024.
Dividend & Returns
What is ANL's return on equity?
Adlai Nortye Ltd. (ANL) has a return on equity (ROE) of -99.0%. Negative ROE indicates the company is unprofitable.
What is Adlai Nortye Ltd.'s free cash flow?
Adlai Nortye Ltd. (ANL) had negative free cash flow of $66.9M in fiscal year 2024, likely due to heavy capital investments.